Gosset Ownership
Private
Therapeutic Areas
Stage
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
HighField Biopharmaceuticals General Information
HighField Biopharmaceuticals has demonstrated promising safety and efficacy signals in early clinical studies. Its lead program HF1K16 showed good tolerability and immune modulation in solid tumor patients with preliminary efficacy signals, especially in glioma cohorts. The company’s mRNA-based HFG1 program has shown significant weight loss and HbA1c reduction in diabetic monkeys. IND clearance was granted in China to begin a Phase I trial of the novel T cell engager HF50 targeting solid tumors[3][5][9].
Contact Information
Drug Pipeline
K1
Phase 1Key Partnerships
HighField Biopharmaceuticals Funding
No funding data available
To view HighField Biopharmaceuticals's complete valuation and funding history, request access »